東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Genetic Predictors of Bevacizumab-In...

Li, Megan S.

Linked to FindBook

Google Book

Amazon

博客來

Genetic Predictors of Bevacizumab-Induced Hypertension.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Genetic Predictors of Bevacizumab-Induced Hypertension./
Author:	Li, Megan S.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2017,
Description:	227 p.
Notes:	Source: Dissertation Abstracts International, Volume: 78-09(E), Section: B.
Contained By:	Dissertation Abstracts International78-09B(E).
Subject:	Genetics. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10261288
ISBN:	9781369737790

Genetic Predictors of Bevacizumab-Induced Hypertension.
Li, Megan S.

Genetic Predictors of Bevacizumab-Induced Hypertension. - Ann Arbor : ProQuest Dissertations & Theses, 2017 - 227 p.

Source: Dissertation Abstracts International, Volume: 78-09(E), Section: B.

Thesis (Ph.D.)--University of California, San Francisco, 2017.

Bevacizumab is a vascular endothelial growth factor-specific angiogenesis inhibitor indicated as an adjunct to chemotherapy for the treatment of several types of cancer. Hypertension is commonly observed during bevacizumab treatment, and high-grade toxicity can limit therapy and lead to other cardiovascular complications. The factors that contribute to interindividual variability in blood pressure response to bevacizumab treatment are not well understood. To identify novel mechanisms of bevacizumab-induced hypertension, the research in this dissertation explored genetic variation associated with the toxicity. A sequencing analysis of whole exomes and candidate gene regulatory regions identified a genomic region between SLC29A1 and HSP90AB1 containing several variants associated with hypertension in colorectal cancer patients with extreme toxicity phenotypes. Functional experiments in human endothelial cells provide evidence that variation in SLC29A1 (ENT1) expression is associated with altered adenosine signaling that modulates the synthesis of vasodilatory molecules during bevacizumab treatment. These results suggest that increased basal expression of SLC29A1 and low extracellular adenosine levels may sensitive patients to a rise in blood pressure during bevacizumab exposure. Additionally, a genome-wide association study of a larger, independent cohort of breast cancer patients identified variants associated with cumulative bevacizumab dose at the first occurrence of hypertension. Several of these SNPs are located within or near genes of biological interest (MSH6, SDC4, ASB5, SMYD5) and may highlight additional mechanisms important in the pathogenesis of the toxicity. Collectively, the studies in this dissertation identified novel genetic loci that potentially modify the risk of developing bevacizumab-induced hypertension. The results of this research will advance understanding of the biological mechanism of this adverse drug reaction and should be considered in the future use and development of angiogenesis inhibitors.

ISBN: 9781369737790Subjects--Topical Terms:

530508
Genetics.

Genetic Predictors of Bevacizumab-Induced Hypertension.
LDR:02985nmm a2200301 4500 001 2124077
005 20171023101707.5
008 180830s2017 ||||||||||||||||| ||eng d
020 $a 9781369737790
035 $a (MiAaPQ)AAI10261288
035 $a AAI10261288
040 $a MiAaPQ $c MiAaPQ
100 1 $a Li, Megan S. $3 3286051
245 1 0 $a Genetic Predictors of Bevacizumab-Induced Hypertension.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2017
300 $a 227 p.
500 $a Source: Dissertation Abstracts International, Volume: 78-09(E), Section: B.
500 $a Adviser: Deanna L. Kroetz.
502 $a Thesis (Ph.D.)--University of California, San Francisco, 2017.
520 $a Bevacizumab is a vascular endothelial growth factor-specific angiogenesis inhibitor indicated as an adjunct to chemotherapy for the treatment of several types of cancer. Hypertension is commonly observed during bevacizumab treatment, and high-grade toxicity can limit therapy and lead to other cardiovascular complications. The factors that contribute to interindividual variability in blood pressure response to bevacizumab treatment are not well understood. To identify novel mechanisms of bevacizumab-induced hypertension, the research in this dissertation explored genetic variation associated with the toxicity. A sequencing analysis of whole exomes and candidate gene regulatory regions identified a genomic region between SLC29A1 and HSP90AB1 containing several variants associated with hypertension in colorectal cancer patients with extreme toxicity phenotypes. Functional experiments in human endothelial cells provide evidence that variation in SLC29A1 (ENT1) expression is associated with altered adenosine signaling that modulates the synthesis of vasodilatory molecules during bevacizumab treatment. These results suggest that increased basal expression of SLC29A1 and low extracellular adenosine levels may sensitive patients to a rise in blood pressure during bevacizumab exposure. Additionally, a genome-wide association study of a larger, independent cohort of breast cancer patients identified variants associated with cumulative bevacizumab dose at the first occurrence of hypertension. Several of these SNPs are located within or near genes of biological interest (MSH6, SDC4, ASB5, SMYD5) and may highlight additional mechanisms important in the pathogenesis of the toxicity. Collectively, the studies in this dissertation identified novel genetic loci that potentially modify the risk of developing bevacizumab-induced hypertension. The results of this research will advance understanding of the biological mechanism of this adverse drug reaction and should be considered in the future use and development of angiogenesis inhibitors.
590 $a School code: 0034.
650 4 $a Genetics. $3 530508
650 4 $a Pharmacology. $3 634543
650 4 $a Bioinformatics. $3 553671
690 $a 0369
690 $a 0419
690 $a 0715
710 2 $a University of California, San Francisco. $b Pharmaceutical Sciences and Pharmacogenomics. $3 1023490
773 0 $t Dissertation Abstracts International $g 78-09B(E).
790 $a 0034
791 $a Ph.D.
792 $a 2017
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10261288